Interleukin 20 Discovery, Receptor Identification, and Role in Epidermal Function

  title={Interleukin 20 Discovery, Receptor Identification, and Role in Epidermal Function},
  author={Hal Blumberg and Darrell Conklin and Wenfeng Xu and Angelika Grossmann and Ty Brender and Susan Carollo and Maribeth A. Eagan and Don Foster and Betty Haldeman and Angela K. Hammond and Harald S. Haugen and Laura Jelinek and James Darrel Kelly and Karen Madden and Mark F Maurer and Julia Parrish-Novak and Donna E. Prunkard and Shannon Sexson and Cindy A. Sprecher and Kimberly S. Waggie and Jim West and Theodore E. Whitmore and Lena Yao and Melanie K. Kuechle and Beverly A. Dale and Yasmin Aladin Chandrasekher},

Figures from this paper

IL-20: biological functions mediated through two types of receptor complexes.
  • U. Wegenka
  • Biology
    Cytokine & growth factor reviews
  • 2010
The Therapeutic Potential of Anti-Interleukin-20 Monoclonal Antibody
It is demonstrated that IL-20 plays pivotal roles in rheumatoid arthritis, osteoporosis, and breast cancer-induced osteolysis, and in vitro and in vivo data and clinical samples demonstrated that anti-IL-20 monoclonal antibody ameliorates arthritis severity and protects against ovariectomized-induced bone loss.
Interleukins 19, 20, and 24 Signal through Two Distinct Receptor Complexes
Results demonstrate that, although this cytokine subfamily exhibits receptor complex redundancy, there are differences in ligand/receptor interactions and in signal transduction that may lead to specificity and a distinct biology for each cytokine.
IL-10-related cellular cytokines and their receptors: new targets for inflammation and cancer therapy
An updated overview of the molecular and functional properties of these molecules is provided and the associated patent literature is discussed.
Structural basis for receptor sharing and activation by interleukin-20 receptor-2 (IL-20R2) binding cytokines
The crystal structure of the IL-20/IL-20R1/IL -20R2 complex reveals how type I and II complexes discriminate cognate from noncognate ligands and defines how the receptor–cytokine interfaces are affinity tuned to allow distinct signaling through a receptor complex shared by three different ligands.
Cloning and characterization of mouse IL-22 binding protein
MIL-22BP binds to mouse and human IL-22 and neutralizes STAT3 activation induced by both cytokines in human and rat hepatoma cell lines, and could be upregulated by LPS stimulation in mouse monocytes.
Crystal Structure of Interleukin-19 Defines a New Subfamily of Helical Cytokines*
It is proposed that IL-19, IL-20, and other putative members of the proposed IL-10 family together form a distinct subfamily of helical cytokines.
Conservation of the genomic structure and receptor-mediated signaling between human and rat IL-24
Using human colon cancer cell lines with somatic knockout of either the mutant or the wild-type k-ras allele, it is demonstrated that the human IL-24 receptors also are upregulated by oncogenic ras, providing strong experimental evidence that MOB-5 is indeed the rat homolog of human IL,24.
Interleukin‐20 as a Target in Psoriasis Treatment
It is found that blocking IL‐20 signaling in psoriasis improves Psoriasis treatment, suggesting that IL-20 is a potential target in psOriasis treatment.


Identification and functional characterization of a second chain of the interleukin‐10 receptor complex
The CRFB4 chain, which is designated as the IL‐10R2 or IL‐ 10Rβ chain, serves as an accessory chain essential for the activeIL‐10 receptor complex and to initiate IL‐8‐induced signal transduction events.
Interleukin (IL)-22, a Novel Human Cytokine That Signals through the Interferon Receptor-related Proteins CRF2–4 and IL-22R*
IL-22 does not inhibit the production of proinflammatory cytokines by monocytes in response to LPS nor does it impact IL-10 function on monocytes, but it has modest inhibitory effects on IL-4 production from Th2 T cells.
Demonstration and functional analysis of IL-10 receptors in human epidermal cells: decreased expression in psoriatic skin, down-modulation by IL-8, and up-regulation by an antipsoriatic glucocorticosteroid in normal cultured keratinocytes.
The results provide the first evidence for a role of the IL-10R gene in the homeostasis of the epidermis and substantiate the concept of a loss of negative regulatory peptides as a step in the eruption of psoriasis.
Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor.
The cloning of the human IL-TIF cDNA is reported, which shares 79% amino acid identity with mouse IL- TIF and 25% identity withhuman IL-10, suggesting that this cytokine contributes to the inflammatory response in vivo.
Cloning and Characterization of IL-10-Related T Cell-Derived Inducible Factor (IL-TIF), a Novel Cytokine Structurally Related to IL-10 and Inducible by IL-91
Experiments concerning the mechanism regulating IL-TIF expression in T cells indicate that IL-9 induction is rapid, does not require protein synthesis, and depends on the activation of the Janus kinase (JAK)-STAT pathway.
IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.
Investigations demonstrate the major importance of IL-10 in psoriasis and show thatIL-10 administration represents a new therapeutic approach, and is the first report on IL- 10 therapy for cutaneous disorders.
Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI.
Both hIL-10 and mouse IL-10 sustain the viability of a mouse mast cell line in culture, but B CRFI lacks comparable activity in this assay, suggesting that BCRFI may have conserved only a subset of hIL -10 activities.
Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes
Signal transduction through receptors for interferons Type I and Type II, and interleukin 10 (IL-10) is described in detail, and a complex between tissue factor and coagulation factor VIIa, and two new receptors related to the class II cytokine receptor family are discussed.